Compare WULF & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | GKOS |
|---|---|---|
| Founded | 1952 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.9B |
| IPO Year | 1999 | 2015 |
| Metric | WULF | GKOS |
|---|---|---|
| Price | $13.87 | $105.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $17.96 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 30.3M | 666.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $168,455,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $139.73 | $23.39 |
| Revenue Next Year | $178.09 | $27.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 20.28 | ★ 32.33 |
| 52 Week Low | $2.06 | $73.16 |
| 52 Week High | $18.51 | $130.23 |
| Indicator | WULF | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 36.71 |
| Support Level | $11.30 | $104.72 |
| Resistance Level | $16.76 | $106.52 |
| Average True Range (ATR) | 1.30 | 4.82 |
| MACD | -0.37 | -1.34 |
| Stochastic Oscillator | 13.34 | 21.68 |
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.